Menu
Recruiting NCT07309601

Sucrase-Isomaltase (SI) Genes and Meal Load

No phase Interventional IBS - Irritable Bowel Syndrome Sucrase-Isomaltase Deficiency

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Meal load.
Who it may be relevant to
Registry conditions: IBS - Irritable Bowel Syndrome, Sucrase-Isomaltase Deficiency. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Sweden
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparison of a Meal Load Between Normal and Functional Variants of the Sucrase-isomaltase (SI) Gene in IBS

Overview

The goal of this interventional study is to examine whether those patients with irritable bowel syndrome (IBS) and a reduced abitility do degrade starch and sugar (lowe levels of enzymes) have lower raise in blood glucose after a meal than those with normal expression of enzymes. We also want to examine whether those IBS patients with reduced enzyme levels have increased bowel symptom in relation to this meal. The main questions it aims to answer are: Does reduced ability to degrade starch and sugar due to less enzyme activity lead to lower increase in blood glucose after a meal? Does reduced ability to degrade starch and sugar due to less enzyme activity lead to increased bowel symptoms after a meal?

Detailed description

All IBS patients who have been included in the previous studies (Dnr 2017/171, Dnr 2021-05407-01 and Dnr 2023-01377-01) and have been genetically tested for the sucrase-isomaltse enzyme (SI gene) and other genes encoding enzymes important for carbohydrate absorption will be called and asked if they want to participate in the present study.

The patient receives a basic questionnaire about lifestyle, health and symptoms over the past 2 weeks, including Rome IV questionnaire, irritable bowel syndrome-severity scoring system (IBS-SSS), and visual analog scale for irritable bowel syndrome (VAS-IBS) to be completed at home and brought to the test. The patient comes to the clinic fasting (only allowed to drink water at home in the morning). A plastic tube is placed in the arm, and the patient has to eat a sugar-rich meal during 15 minutes. Blood samples are drawn 10 minutes before start, at the start of the meal, and 10, 20, 30, 45, 60, 90, och 120 minutes aftrewards. Blood samples are analyzed for glucose levels in blood at the Department of Clinical Chemistry, at the hospital. At the same time points as blood sampling, the patient has to complete a questionnaire about bowel symptoms.

Raise in blood glucose and bowel symptoms will be compared between those with reduced enzyme activity and those with normal enzyme activity. The correlation between blood glucose levels and symptoms will be calculated.

Interventions

  • Dietary supplement Meal load
    Meal load during 15 minutes

Primary outcome measures

  • Changes of blood glucose after a meal intake [Time frame: 2 hours]
Secondary outcome measures (1)
  • Changes of gastrointestinal and extraintestinal symptoms after a meal intake assesssed by self-reported completion on visual analog scales [Time frame: 2 hours]

Eligibility criteria

Inclusion criteria

  • Diagnosis of irritable bowel syndrome (IBS)
  • Gene testing has been conducted regarding genes regulating the production of sucrase-isomaltase ensymes in previous dietary interventions using the starch- and sucrose reduced diet (SSRD) or multi-center study.

Exclusion criteria

  • Diagnosis of inflammatory bowel disease, celiac disease, bile salt malabsorption, gastroenteritis or enteric dysmotility
  • Severe food allergy
  • Serious heart-, lung-, cardiovascular-, malignant- or mental illness
  • Ongoing eating disorder
  • Pregnancy
  • Recent major gastrointestinal surgery
  • Alcohol and/or drug addiction

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Sweden · 1 center
  • Skåne University Hospital — Malmö

Identifiers

NCT: NCT07309601 · 2025-07563-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗